American Bio Medica to Present at the Upcoming EdgeWater Research Spring 2006 Small/Micro Cap Conference

KINDERHOOK, N.Y. -- (BUSINESS WIRE) -- April 19, 2006 -- American Bio Medica Corporation (NASDAQ: ABMC), a global provider of immunoassay diagnostic test kits, today announced that the Company will be a featured presenter at the upcoming EdgeWater Research Spring 2006 Small/Micro Cap Conference to be held on Friday, April 21, 2006 at the Grand Hyatt Hotel in Denver, Colorado.

ABMC's Chief Executive Officer, Stan Cipkowski, will use the conference's visual presentation format to present ABMC's progress on strategic alliance development and further diversification of its products and services to the criminal justice, workplace and clinical markets.

For more information on ABMC or its drug testing products, please visit www.abmc.com

About EdgeWater Research Partners, LLC

EdgeWater Research Partners, LLC is an independent micro cap equities research company representing the research of David Lavigne. EdgeWater follows a number of undiscovered small and micro cap stocks through both individual research and its monthly publication, The EdgeWater Micro Monthly. EdgeWater's research is distributed to its subscriber base, and is also available on a piece by piece basis on the Company's website, www.edgewaterresearch.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R) and Rapid TOX(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(TM) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2005, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

    CONTACT: ABMC
             Stan Cipkowski, 800-227-1243, Ext 106
              OR
             BPC Financial Marketing
             John Baldissera, 800-368-1217

    SOURCE: American Bio Medica Corporation